Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.
about
Intranasal BMP9 Ameliorates Alzheimer Disease-Like Pathology and Cognitive Deficits in APP/PS1 Transgenic Mice.Roles of tau protein in health and disease.Role of Endoplasmic Reticulum Stress in Learning and Memory Impairment and Alzheimer's Disease-Like Neuropathology in the PS19 and APPSwe Mouse Models of Tauopathy and Amyloidosis.Tau PET imaging: present and future directions.Eyetracking Metrics in Young Onset Alzheimer's Disease: A Window into Cognitive Visual Functions.Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches.Why do trials for Alzheimer's disease drugs keep failing? A discontinued drug perspective for 2010-2015.Research update on Alzheimer's disease and introduction to the Expert Review of Neurotherapeutics special issue.New routes in frontotemporal dementia drug discovery.Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.Alzheimer's disease drug development pipeline: 2017.The past, present, and future of disease-modifying therapies for Alzheimer's disease.Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial.Tau-mediated Neurodegeneration and Potential Implications in Diagnosis and Treatment of Alzheimer's Disease.Modeling Prion-Like Processing of Tau Protein in Alzheimer's Disease for Pharmaceutical Development.Recent Progress in the Pharmacotherapy of Alzheimer's Disease.A Protein Aggregation Inhibitor, Leuco-Methylthioninium Bis(Hydromethanesulfonate), Decreases α-Synuclein Inclusions in a Transgenic Mouse Model of Synucleinopathy."Tau immunotherapy: Hopes and hindrances".Tau-based therapies in neurodegeneration: opportunities and challenges.Tau Diagnostics and Clinical Studies.Dysregulation of Rab5-Mediated Endocytic Pathways in Alzheimer's Disease.From Mitochondrial Function to Neuroprotection-an Emerging Role for Methylene Blue.Alzheimer's disease hypothesis and related therapies.Corticobasal degeneration: key emerging issues.Focused ultrasound as a novel strategy for Alzheimer disease therapeutics.Efficacy of Hearing Aids on the Cognitive Status of Patients with Alzheimer's Disease and Hearing Loss: A Multicenter Controlled Randomized Trial.Thiamine diphosphate reduction strongly correlates with brain glucose hypometabolism in Alzheimer's disease, whereas amyloid deposition does not.Targeting Alzheimer's Disease at the Right Time and the Right Place: Validation of a Personalized Approach to Diagnosis and Treatment.An Overview on the Clinical Development of Tau-Based Therapeutics.Setbacks in Alzheimer research demand new strategies, not surrender.Progress and Challenges in Frontotemporal Dementia Research: A 20-Year Review.Transplantation of Human Menstrual Blood-Derived Mesenchymal Stem Cells Alleviates Alzheimer's Disease-Like Pathology in APP/PS1 Transgenic Mice.The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade.The Neurotoxic Role of Extracellular Tau Protein.Efficacy of curcumin for age-associated cognitive decline: a narrative review of preclinical and clinical studies.Suppressor of Cytokine Signaling 3: Emerging Role Linking Central Insulin Resistance and Alzheimer’s Disease.Research Progress in the Pathogenesis of Alzheimer's DiseaseQuestions concerning the role of amyloid-β in the definition, aetiology and diagnosis of Alzheimer's diseaseHighly specific and selective anti-pS396-tau antibody C10.2 targets seeding-competent tau
P2860
Q30362847-265A7239-16B4-4C11-AA48-275D916D1FE7Q33559303-3F8E6233-C8A1-4600-B6B0-723B861BB0B7Q33903715-BC951218-3E01-472A-A5A6-F5544336D3A1Q34680852-CA684EAB-D0B5-4A31-A5FC-98B3EB7718A6Q38616754-32C03858-3D92-4F86-A634-5EF21743B2DEQ38666247-82D92484-F49E-40E1-AF30-AD77773880F3Q38810754-8D2ECC44-BAD7-4989-8F3C-60B4F04B9099Q39027024-570B74A5-413A-4C25-9FC3-B630D8A0F771Q39344391-5F2D17AE-4153-47F8-A4A8-6CDEA8717368Q41592614-7C022A09-1854-432E-B746-0822121AB9A5Q42655757-65E90ABF-BF43-43BC-B717-EFFF7713F4B8Q46244313-8BAC6706-7E0F-43D3-B87B-CC8BD226EC80Q47147322-44871A2C-91C3-4D88-A020-18AA3090DB89Q47296152-EB8316AB-C570-4C70-B162-CA740BADEB51Q47308968-F81BD521-C5F4-4E50-AE89-77E998E6FFA3Q47425364-75ABC7A7-E5FF-456B-AF5D-26F567AC6041Q47548619-8D8FB574-7314-4168-B382-2668FBE35C16Q47629452-F878D515-0B32-418E-BD08-C2C1B0491C4CQ47689697-F19D7F82-5919-4107-9D5D-5EB57AE0808BQ47870437-1FC4DB4D-570E-4534-8392-CB04EFD7E50DQ47875216-A8638F8B-EE01-47B7-BF3C-AB700F10E577Q48004149-E2AE6D22-C0CE-4749-9CE9-080DC67B8407Q49762112-43ABC895-5E52-4BA9-9A9C-4F8E3A37CE18Q50074075-2CF6018F-C43E-4B65-9842-225863E6E46BQ50239472-E103175C-52F2-4C7A-9C62-C5F3687B56EAQ50309701-DC403B70-CA99-4324-94E4-7F7045E27679Q51746356-844CF568-49A8-45CE-BD97-25B5FF1CFB0BQ51765788-8AB70776-F662-4C81-A79D-5166B4A01842Q52594209-D0964D4A-9CE5-4881-83DA-CC4BB56CD263Q52683121-BE207104-E162-4A53-90F6-6D4EEC0EBE13Q53441607-754CBF9F-7D5E-4700-B810-CD9E7CCA759AQ54217663-1D6C8018-7D69-4E7E-92D4-990F4B9B2B4FQ54977832-095CD1CB-8F66-4D46-BF13-9500479EC38BQ55080849-0E213DB0-ACD5-489A-A7F5-262966EE6B41Q55333133-FB73678E-1E5F-4B43-80DA-4AB78A2EDA66Q55405257-A0BC59E2-A5FB-4015-8DAA-61935358D8D6Q57177048-BDA9AE13-7347-4213-9256-186B3D0E5942Q57800439-1FB096F0-BEB7-4AAD-A633-BD3D4D7149A1Q58566972-50802C46-D664-43E0-9507-9C5A5E9C7455
P2860
Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Efficacy and safety of tau-agg ...... , parallel-arm, phase 3 trial.
@en
Efficacy and safety of tau-agg ...... , parallel-arm, phase 3 trial.
@nl
type
label
Efficacy and safety of tau-agg ...... , parallel-arm, phase 3 trial.
@en
Efficacy and safety of tau-agg ...... , parallel-arm, phase 3 trial.
@nl
prefLabel
Efficacy and safety of tau-agg ...... , parallel-arm, phase 3 trial.
@en
Efficacy and safety of tau-agg ...... , parallel-arm, phase 3 trial.
@nl
P2093
P2860
P921
P1433
P1476
Efficacy and safety of tau-agg ...... d, parallel-arm, phase 3 trial
@en
P2093
Bjoern O Schelter
Charles S Davis
Claude M Wischik
Damon J Wischik
Giovanni B Frisoni
Gordon K Wilcock
Hans J Moebius
Jiri H Hardlund
John M D Storey
Karin A Kook
P2860
P304
P356
10.1016/S0140-6736(16)31275-2
P407
P577
2016-11-16T00:00:00Z